Sanofi gains despite complete response letter

Sanofi (Euronext:SAN; NYSE:SNY) shares rose Friday after the company reported earnings showing growth of its multiple sclerosis drugs, combined with double-digit gains from its vaccine business and rare disease portfolio, are offsetting continued headwinds in its diabetes and cardiovascular franchises.

The stock held the day's gains in New York trading after news that FDA had issued a complete response letter for rheumatoid arthritis candidate sarilumab. ...